(41 days)
The AURORA MRI system is an imaging device, and is intended to provide the physician with physiological and clinical information obtained noninvasively and without the use of ionizing radiation. The MR system produces transverse, coronal, sagittal, and oblique cross-sectional images that display the internal structure of the extremities (breast tissue, axilla, and chest wall local to the breast). The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician. these images provide information that can be useful in diagnosis determination.
The AURORA is a dedicated breast MRI system intended to be used as an adjunct to conventional breast screening methods.
- . Anatomical region: Breast tissue, axilla, and chest wall local to the breast
- . Nucleus excited: Proton
- Diagnostic uses: 2D, 3D T1-/T2-weighted imaging .
T1, T2, proton density measurements Image processing
- . Imaging Capabilities: 2D Spin Echo (SE) 2D/3D Gradient Echo (GRE) Fat Suppression
- . Imaging Processing: Image Subtraction Image Filtering
The modified AURORA is identical to the AURORA breast imaging system cleared by the FDA through K032082 except for the addition of the RODEO Spiral 3D pulse sequence.
The provided 510(k) summary for the AURORA Magnetic Resonance Diagnostic Device (K052698) describes modifications to an existing MRI system. However, it does not contain the detailed information necessary to fully answer all aspects of your request, particularly regarding specific acceptance criteria, a study proving performance against those criteria, or the use of AI.
The document primarily focuses on demonstrating substantial equivalence to a predicate device (K032082) after adding a new pulse sequence (RODEO Spiral 3D). It states that "Testing was performed to validate the safety and performance of the AURORA with the new pulse sequence," but it does not elaborate on the nature of this testing, the acceptance criteria, or the results.
Here's an analysis based on the provided text, highlighting what is present and what is missing:
Acceptance Criteria and Device Performance:
The document does not explicitly state quantitative acceptance criteria or a direct comparison of device performance against such criteria. The testing was focused on validating the safety and performance of the new pulse sequence.
Missing Information: A table of acceptance criteria and reported device performance is not provided in the summary. The summary is primarily a regulatory filing for substantial equivalence based on a new pulse sequence, not a detailed clinical or performance study report.
Sample Size and Data Provenance:
The document states "Testing was performed to validate the safety and performance of the AURORA with the new pulse sequence."
Missing Information: The summary does not specify the sample size used for any test set or the data provenance (e.g., country of origin, retrospective/prospective).
Number and Qualifications of Experts for Ground Truth:
Missing Information: There is no mention of experts used to establish ground truth for a test set, as this level of detail is not typically included in a 510(k) summary that focuses on validating a pulse sequence addition.
Adjudication Method:
Missing Information: No adjudication method is mentioned, as the summary does not detail any studies involving multiple readers or the establishment of ground truth in that way.
Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
Missing Information: A multi-reader multi-case (MRMC) comparative effectiveness study is not mentioned. The document does not describe any human reader studies, either with or without AI assistance. The device is an MRI system, not an AI-powered diagnostic tool.
Standalone (Algorithm Only) Performance Study:
Missing Information: A standalone performance study for an algorithm is not described. This device is a magnetic resonance imaging device, and the submission is about a new pulse sequence for image acquisition, not an AI algorithm for image interpretation.
Type of Ground Truth Used:
Missing Information: The summary does not describe the type of ground truth used, as it doesn't detail any studies requiring such a ground truth for diagnostic accuracy. The testing mentioned is for the "safety and performance" of a new MRI pulse sequence, which would typically involve image quality assessments or phantom studies, rather than clinical ground truth like pathology or outcomes data.
Sample Size for Training Set:
Missing Information: There is no mention of a training set sample size. This is consistent with the nature of the device being an MRI system with a new pulse sequence, rather than an AI or machine learning algorithm that requires a training set.
How Ground Truth for Training Set was Established:
Missing Information: As no training set is mentioned, there is no information on how its ground truth might have been established.
In summary, the provided 510(k) summary is a regulatory document focused on demonstrating substantial equivalence for a hardware/software modification (addition of a pulse sequence) to an existing MRI device. It does not contain the detailed performance study information, including acceptance criteria, sample sizes, expert involvement, or AI-specific data, that your request outlines.
{0}------------------------------------------------
NOV - 8 2005
510(k) Summary for the
AURORA Magnetic Resonance Diagnostic Device
(per 21 CFR 807.92)
1. SPONSOR
Aurora Imaging Technology Inc. 39 High Street North Andover, MA 01845
| Contact Person: | Michael A. Douglas |
|---|---|
| Telephone: | 978.975.7530 x4345 |
Date Prepared: September 12, 2005
2. DEVICE NAME
Proprietary Name: Aurora Common/Usual Name: Magnetic Resonance Imaging Device Classification Name: Maqnetic Resonance Diagnostic Device
3. PREDICATE DEVICES
Aurora MRI System (K032082)
4. Device Description
The modified AURORA is identical to the AURORA breast imaging system cleared by the FDA through K032082 except for the addition of the RODEO Spiral 3D pulse sequence.
5. INTENDED USE
The AURORA MRI system is an imaging device, and is intended to provide the physician with physiological and clinical information obtained noninvasively and without the use of ionizing radiation. The MR system
{1}------------------------------------------------
produces transverse, coronal, sagittal, and oblique cross-sectional images that display the internal structure of the extremities (breast tissue, axilla, and chest wall local to the breast). The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density spin-lattice relaxation time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician. these images provide information that can be useful in diagnosis determination.
The AURORA is a dedicated breast MRI system intended to be used as an adjunct to conventional breast screening methods.
- . Anatomical region: Breast tissue, axilla, and chest wall local to the breast
- . Nucleus excited: Proton
- Diagnostic uses: 2D, 3D T1-/T2-weighted imaging .
T1, T2, proton density measurements Image processing
- . Imaging Capabilities: 2D Spin Echo (SE) 2D/3D Gradient Echo (GRE) Fat Suppression
- . Imaging Processing: Image Subtraction Image Filtering
6. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE
Aurora Imaging Technology, Inc., makes a claim of substantial equivalence of the modified AURORA to the predicate AURORA (K032082) based on similarities in intended use, design, and technological and operational characteristics. Both are indicated for magnetic resonance imaging of the breast. Both systems use the same hardware and software except that the modified device includes a new pulse sequence for RODEO Spiral 3D.
7. Testing
Testing was performed to validate the safety and performance of the AURORA with the new pulse sequence.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the department's name around the perimeter. In the center is an abstract symbol that resembles an eagle or a bird in flight. The symbol is composed of three curved lines.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV - 8 2005
Mr. Michael A. Douglas Director of QA and Regulatory Affairs Aurora Imaging Technology, Inc. 39 High Street NORTH ANDOVER MA 01845
Re: K052698
Trade/Device Name: AURORA MRI System Regulation Number: 21 CDR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: II Product Code: LNH Dated: September 23, 2005 Received: October 12, 2005
Dear Mr. Douglas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it mav be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxxx | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|---|---|
| 21 CFR 884.xxxx | (Obstetrics/Gynecology) | 240-276-0115 |
| 21 CFR 892.xxxx | (Radiology) | 240-276-0120 |
| Other | 240-276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Nancy C. Brogdon
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
follow the procedures outlined in the "A Suggested Approach to Resolving Least Burdensome Issues" document. It is available on our Center web page at: http://www.fda.gov/cdrh/modact/leastburdensome.html
510(k) Number:
K052698
Aurora
Device Name:
Indications for Use:
The AURORA MRI system is an Imaging device, and is intended to provide the physician with physiological and clinical information obtained non-invasively and without the use of lonizing radiation. The MR system produces transverse, coronal, sagittel, and oblique cross-sectional images that display the internal structure of the extremities (breast tissue, axilla, and chest wall local to the breast). The images produced by the MR system reflect the spatial distribution of protons (hydrogen nuclei) exhibiting magnetic resonance. The NMR properties that determine the image appearance are proton density spin-lattice relaxstion time (T1), spin-spin relaxation time (T2), and flow. When interpreted by a trained physician, these images provide information that can be useful in diagnosis determination.
- Anatomical region: Breast tissue, axilla, and chest wall local to the breast .
- Nucleus excited: Proton ●
- Diagnostic uses: 2D. 3D T1-772-weighted imaging
| Imaging Capabilities: | T1, T2, proton density measurementsImage processing2D Spin Echo (SE)2D/3D Gradient Echo (GRE)Fat Suppression |
|---|---|
| Imaging Processing: | Image SubtractionImage Filtering |
PRESCRIPTION Use ✓
(21 CFR 801 SUBPART D)
Over-The-Counter USE
(21 CFR 801 SUBPART C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Nancy Brogdon
Division Sign Off
Division Sign-Off Division of Reproductive, Abdominal and Radiological Devices 510(k) Number
Aurora Imaging Special 510(k) September 23, 2005 AURORA SPIRAL Pulse Sequence
Confidential Page i
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.